Welcome to our dedicated page for Alzamend Neuro news (Ticker: ALZN), a resource for investors and traders seeking the latest updates and insights on Alzamend Neuro stock.
Alzamend Neuro, Inc. (NASDAQ: ALZN) is a clinical-stage biopharmaceutical company developing novel treatments for Alzheimer’s disease, bipolar disorder, major depressive disorder and post-traumatic stress disorder. News about ALZN often centers on the progress of its two main product candidates, AL001 and ALZN002, as well as financing transactions and corporate actions disclosed through press releases and SEC filings.
Investors following ALZN news can expect detailed updates on the company’s Phase II "Lithium in Brain" clinical program for AL001. These reports describe head-to-head studies of AL001 versus marketed lithium carbonate products, including enrollment milestones, dosing of the first patient, and completion of the clinical portion of trials in healthy subjects. Company announcements also highlight collaborations with Massachusetts General Hospital, Tesla Dynamic Coils BV and QMENTA to support high-resolution brain imaging and AI-driven analysis of lithium distribution.
Alzamend Neuro’s news flow also includes information on its ALZN002 active immunotherapy program targeting beta-amyloid in Alzheimer’s, operational developments in clinical trial management, and capital-raising activities such as private placements of preferred stock and related warrant issuances. Corporate updates, including reverse stock split decisions and governance matters reported on Form 8-K, are frequently summarized in press releases.
This ALZN news page aggregates these updates so readers can review clinical milestones, financing events and regulatory disclosures in one place. For those tracking the development of AL001 and ALZN002, or monitoring Alzamend Neuro’s Nasdaq-listed common stock, the news feed offers a consolidated view of the company’s publicly reported activities and announcements.
Alzamend Neuro (Nasdaq: ALZN) celebrates its recent Nasdaq listing by ringing the opening bell on July 12, 2021. The event is led by CEO Stephan Jackman and Chairman William B. Horne, marking a significant milestone for stockholders and the ongoing fight against Alzheimer’s disease. Alzamend has raised approximately $14.4 million through its IPO, which will fund operations and clinical trials. The company is advancing its therapeutic candidate, AL001, and aims to develop innovative treatments for Alzheimer's and other neurodegenerative diseases.
Ault Global Holdings announced that Alzamend Neuro submitted an IND application to the FDA for a Phase 1 clinical study of AL001, a lithium-based therapy for Alzheimer's-related dementia. This IND marks a significant step in Alzamend's pipeline development. Following this study, Alzamend plans a Phase 1/2a trial to assess safety and effectiveness. With over 47 million people affected by dementia globally, the economic burden is immense, costing the U.S. approximately $355 billion in 2021 alone. Ault holds 5.3 million shares of Alzamend, showing a strong commitment to the development of treatments for neurodegenerative diseases.
Alzamend Neuro (Nasdaq: ALZN) has submitted an investigational new drug (IND) application to the FDA for the Phase 1 clinical study of AL001, a lithium-based therapy for Alzheimer's related dementia. The initial study aims to assess safe dosing, followed by a Phase 1/2a trial to evaluate safety and preliminary efficacy. Alzamend believes AL001 may enhance current lithium treatments. Preclinical data suggests it improves cognitive function compared to lithium carbonate treatments. The economic impact of Alzheimer's is significant, with high lifetime care costs.
Alzamend Neuro has successfully closed its initial public offering (IPO) of 2,500,000 shares, plus a full exercise of the underwriter's over-allotment option resulting in a total of 2,875,000 shares priced at $5.00 per share. The gross proceeds from the offering are approximately $14.4 million. This funding will support Alzamend's mission to develop treatments for neurodegenerative diseases and psychiatric disorders, including Alzheimer's Disease. The company operates with exclusive worldwide licenses for its product candidates from the University of South Florida Research Foundation.
Alzamend Neuro has priced its initial public offering (IPO) of 2,500,000 shares at $5.00 each, aiming to raise gross proceeds of $12.5 million. The IPO is expected to commence trading on Nasdaq under the ticker symbol ALZN on June 15, 2021, with an anticipated closing date of June 17, 2021. Underwriters have a 45-day option to purchase an additional 375,000 shares. Alzamend focuses on developing treatments for neurodegenerative diseases and psychiatric disorders, particularly Alzheimer’s Disease, with two novel product candidates licensed from the University of South Florida.